Recon: FDA rejects Novo Nordisk’s weekly insulin; Pfizer to develop once-daily GLP-1 weight-loss drug
ReconJason Scott
Approval/marketing authorizationBiologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States